Simple presentation of test accuracy may lead to inflated disease probabilities (letter)
Bachmann, L.M.; Steurer, J.; ter Riet, G.

Published in:
BMJ : British medical journal

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)
Download date: 07 Dec 2018
Indiscriminate investigations have adverse effects

Julian H Barth and Richard G Jones

BMJ 2003;326:393-
doi:10.1136/bmj.326.7385.393

Updated information and services can be found at:
http://bmj.com/cgi/content/full/326/7385/393

These include:

References
This article cites 5 articles, 2 of which can be accessed free at:
http://bmj.com/cgi/content/full/326/7385/393#BIBL

Rapid responses
3 rapid responses have been posted to this article, which you can access for free at:
http://bmj.com/cgi/content/full/326/7385/393#responses

You can respond to this article at:
http://bmj.com/cgi/eletter-submit/326/7385/393

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to BMJ go to:
http://bmj.bmjjournals.com/subscriptions/subscribe.shtml
Indiscriminate investigations have adverse effects

**Editor—**The application of evidence based medicine is leading to better treatments by thorough evaluation of treatments based on analyses of risks and benefits. These balance the beneficial clinical gains against the adverse pharmacological and medical effects, using information derived from randomised controlled trials and cost effective-ness studies. In contrast, no such critical approach has been taken for diagnostic tests nor have the consequences and adverse effects of inappropriate investigations been explored. The debate around diagnostic tests has centred largely on minimising the unit costs of the delivery of tests in the light of the enormous increase in the demand for investigations without an obvious and proportionate improvement in health status.¹

The case report by Krishnan et al highlights an adverse effect of an inappropriate investigation in a woman with hypothyroid induced ascites.² The published literature is clear that ascites, and any serous effusion of any aetiology, is associated with raised CA125 concentration.³ Yet despite this evidence, the interpretation of a false positive result triggered a number of adverse effects and consequences—namely, clinical investigations, it is mandatory that the error rate and interferences in the tests are recognised.

**Julian H Barth** consultant in chemical pathology and metabolic medicine
j.h.barth@leeds.ac.uk

**Richard G Jones** senior lecturer and honorary consultant in chemical pathology
Department of Clinical Biochemistry and Immunology, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Leeds LS1 3EX


**Simple presentation of test accuracy may lead to inflated disease probabilities**

**Editor—**We found that conveying information on the accuracy of tests in non-technical language improved doctors’ ability to estimate disease probabilities accurately.¹ We investigated whether doctors might mis-use such non-technical presentation when considering the probability of endometrial cancer in a patient with positive results on transvaginal ultrasonography.

We presented 263 general practitioners in Switzerland with a pre-test probability of 10%, information that the patient was aged 65, and a positive transvaginal ultrasound result. Ninety two general practitioners (group 1) received no information on the test's accuracy; 92 (group 2) were told that the sensitivity of the test was 80% and specificity 60%; and 79 (group 3) were told that a positive result is obtained twice as frequently in women with endometrial cancer as in those without the disease, reflecting a likelihood ratio of 2. The last two statements are numerically equivalent since the likelihood ratio equals sensitivity/(1–specificity).

The table shows that the degree of over-estimation of diagnostic accuracy varied with the presentational format. As we found previously,² almost half of the doctors did not change their probability estimates after they were provided with the patient’s age.

We also found that the non-technical format resulted in 25 of the 79 general practitioners in group 3 (32% (95% confidence interval 22% to 43%)) multiplying their pre-test probability by exactly 2. This is theoretically incorrect since, for example, a likelihood ratio of 2 changes a pre-test probability of 40% to 57% only, not to 80%, which requires a likelihood ratio of 6. Unfortunately, in our study, this mistake helped those respondents who did not change their pre-test probability after being given the patient’s age to get close to the correct value.

---

**Distributions of attributed likelihood ratios in three groups given different summaries of information on diagnostic accuracy**

<table>
<thead>
<tr>
<th>Group</th>
<th>Median attributed likelihood ratio (25th centile, 75th centile)</th>
<th>Comparison between groups</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Original analysis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 (n=92)</td>
<td>9 (3.69)</td>
<td>1 v 2</td>
<td>0.0193</td>
</tr>
<tr>
<td>2 (n=92)</td>
<td>6 (2.22)</td>
<td>1 v 3</td>
<td>0.0001</td>
</tr>
<tr>
<td>3 (n=79)</td>
<td>3 (2.9)</td>
<td>2 v 3</td>
<td>0.0084</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 v (2+3)</td>
<td>0.0006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>All</td>
<td>0.0013</td>
</tr>
<tr>
<td><strong>Stricter analysis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 (n=92)</td>
<td>9 (3.69)</td>
<td>1 v 2</td>
<td>0.0193</td>
</tr>
<tr>
<td>2 (n=92)</td>
<td>6 (2.22)</td>
<td>1 v 3</td>
<td>0.1636</td>
</tr>
<tr>
<td>3 (n=54)</td>
<td>9 (3.17)</td>
<td>2 v 3</td>
<td>0.5682</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 v (2+3)</td>
<td>0.0216</td>
</tr>
<tr>
<td></td>
<td></td>
<td>All</td>
<td>0.0599</td>
</tr>
</tbody>
</table>

*Kruskal-Wallis test.
Formula to convert pre-test probability (P₁) into post-test probability (P₂):
Pre-test odds=likelihood ratio/post-test odds, where pre-test odds = P₁/(1−P₁) and P₂=post-test odds/(1+post-test odds).
Group 1 received no information on the test’s accuracy; group 2 were told that the sensitivity of the test was 80% and specificity 60%; group 3 were told that a positive result is obtained twice as frequently in women with endometrial cancer as those without the disease.
Actual likelihood ratio associated with the test result was 2.25.
changing 10% into 20%, corresponding to an attributed likelihood ratio of 2.25. The table also shows the results after omission of these 25 doctors. The provision of some form of quantitative information still seems advantageous (contrast group 1 vs groups 2 and 3; P=0.0216). However, all comparisons including group 3 are affected by this stricter analysis.

Framing the diagnostic information in the user friendly way that we used for the likelihood ratio may invite doctors to use simple arithmetic and might lead to grossly inflated inferences when pre-test probabilities are high or likelihood ratios are larger.

Lucas M Bachmann research fellow
lucas.bachmann@etvmed.ch

Johann Steurer director
Horten Centre, Zurich University, PO Box Nord, CH-8091 Zurich, Switzerland

Gerben ter Riet senior research fellow
Department of General Practice, Academic Medical Centre, University of Amsterdam, Room J3-534, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands

Effect of computerised evidence based guidelines

Computer support is complex intervention

Eccles et al’s rigorous approach to the evaluation of a computerised decision support system for the management of angina and asthma accounted for many of the flaws in previous trials of computer support.1 They were no doubt disappointed that no effect was seen, probably due to low usage of the system.

Although not discussed in the paper, a possible explanation for this is that, given the comparatively high use of computers required for inclusion in the trial, the practices already used simpler computerised templates to promote collection of process of care data. Practitioners may therefore have perceived little further to be gained by using the more detailed decision support system, particularly if it did not allow easy switching between the guideline and the clinical system.

The study by Eccles et al shows the complexity of interventions in primary care that incorporate computerised decision support systems. This complexity needs to be fully accounted for in designing and evaluating such interventions.2 Even with an apparently well developed piece of software, the trial assumed that offering brief training to a minority of practitioners in each practice would be sufficient for it to be incorporated into the increasingly complex care provided in routine general practice consultations.

Trials of computer support in primary care need to acknowledge this complexity by embedding use of the software in a carefully specified model of care. For the high quality management of chronic disease, this model will probably require subspecialisation within a general practice, as proposed in the new general practitioner contract.3

Providing focused training to key people in a practice and supporting subspecialisation through computer decision support may be a more appropriate approach to chronic disease management in primary care: Future trials of computer support must consider not only the technical features of the software but also the model of service it is supporting and hence the training requirements of potential users. Theoretically derived measures that predict use of the software by practitioners in these trials could provide further important data on the potential role of decision support in clinical practice.

Only then can one truly give computer decision support a fair trial.

Jon D Emery Cancer Research UK clinician scientist
Department of Public Health and Primary Care, University of Cambridge, Institute of Public Health, Cambridge CB2 2QQ, UK. jde10@medschl.cam.ac.uk

Competing interests: None declared.


2 Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sand


Challenge should not be abandoned

Eccles et al performed a methodologically sound study of a poorly developed intervention.4 It is good to be honest and say that systems were not used

Eccles et al have talked about the provision of clinical decision support in their own trial, and the Grade II evidence they produced.5 They state that Prodigy was actually used very little, about seven times a week, and most of the time (88%) users requested to bypass the clinical decision support system.

Opportunity was missed

Eccles et al have talked about the provision of clinical decision support in their own trial, and the Grade II evidence they produced.5 They state that Prodigy was actually used very little, about seven times a week, and most of the time (88%) users requested to bypass the clinical decision support system.

Opportunity was missed

Eccles et al have talked about the provision of clinical decision support in their own trial, and the Grade II evidence they produced.5 They state that Prodigy was actually used very little, about seven times a week, and most of the time (88%) users requested to bypass the clinical decision support system.
Effect may be function of incentive

Error—In their paper Grinshaw et al showed that when incentives available does not result in people using them.1 Analogously, Eccles et al showed that having a decision support system available does not lead to people using it.2 Benson advocated incentives are needed before healthcare workers start using computers.3

In contrast to Eccles et al, van Wijk et al showed effects from a guideline decision support system.4 The general practitioners in these studies had no choice about how to use the tool, whereas such incentives were missing in Eccles et al’s design. We believe that authors of papers describing an evaluation of a decision support system should in the future explicitly discuss incentives for and barriers to using these systems.

Jacobus T van Wyk

Peter W Moorhouse

Marc A M van Wijk

assistant professor

Department of Medical Informatics, Erasmus MC, University Medical Centre Rotterdam, PO Box 1738, NL-3000 DR Rotterdam, Netherlands


Authors’ reply

Error—We agree that complex interventions should ideally be developed through an iterative process. Exceptions to this include evaluating a preformed intervention that would not otherwise be rigorously evaluated. This applied at the outset of our study, although our intervention drew heavily on the iterative development of Prodigy software. We conducted an integrated process evaluation to understand the results better. This will appear in the BMJ shortly.

The NHS has invested large amounts of money in information technology, sometimes for little or no benefit. The evaluation of information technology is complex and multifaceted, but a computerised decision support system can be evaluated as a health technology. Beneficial or detrimental outcomes may be an important element of software development, until someone comes up with better methods of producing unbiased estimates of effectiveness and efficiency we maintain that all health technologies should be considered evaluable in randomised controlled trials.

Important methodological issues exist about the timing and duration of such evaluations, and we agree with Purves that they should be performed on stable systems. Given the cyclical nature of software development and the self belief and enthusiasm of developers, such points must be specified and enacted to avoid self perpetuating iterative cycles of development with the constant promise of jam tomorrow.

Our description of the system that we evaluated is accurate, and none of the authors dissented from it up to the point of publication.

Data were collected from November 1997 to September 2000, with the intervention running during the last 15 months of this time period. The trial was paused for six months while the software team worked on improvements. The rates of presentation of patients we reported equated to opportunities for the system to be used between twice a day and every other day. It is possible that the start of the intervention period, Prodigy software had become available and was delivered to trial practices alongside the study software. Our feedback from practices indicated that at least some asked for the Prodigy software to be turned off. This echoes Beaumont’s letter and implies that increasing the number of the guidelines offered may not be the remedy that Purves suggests.

Two correspondents identified the importance of the issue of training. Contrary to Purves’s letter, two people from each practice were invited to a one day training session and the software was installed within 10 weeks by the computer supplier of two thirds of the trial practices. For the second supplier this interval was almost double, owing to unforeseeable commercial considerations in the company. We acknowledged the importance of training while suggesting that what happened was representative of the real world of primary care. We still believe this to be true but support Emery’s and Purves’s call for better training in service settings.

Fahey et al say that the low levels of use of the system were partly due to requiring the entry of a single Read code and lack of responsiveness to patient specific information. Initially the system could be triggered automatically by a range of specified Read codes in the patient record. It could also be triggered by a clinician entering Read codes selected by the practice and was therefore not a passive method of dissemination. But this was changed in response to requests from the study practices. The automatic triggering was removed and a customisable Read code entry method was used for the final eight months of the intervention. Thus the system did rely on patient specific information.

Emery said that we may have had a ceiling effect due to practices currently using computerised templates. This seems unlikely because only 26% of practices already had...
Novartis was not in breach of code for “inventing” disease

Entriör—Ferriman’s news item is incorrect on at least two counts.

Firstly, it is not true to state that the authority had imposed no penalty on the company for issuing misleading literature. Novartis, like all companies ruled in breach of the Association of the British Pharmaceutical Industry’s code of practice for the pharmaceutical industry, had to undertake that it would take all possible steps to avoid a similar breach of the code in the future.

Novartis voluntarily withdrew the material before the Prescription Medicines Code of Practice Authority had been notified of Dr Novartis being required by the Prescription Medicines Code of Practice Authority had been notified of Dr Novartis, like all companies ruled in breach of the code in the future.

Secondly, the impression from the heading to the article, as above, is misleading. Novartis was not ruled in breach of the code for inventing a disease. Novartis was ruled in breach of the code for giving a misleading impression of the effect of Starlix on cardiovascular mortality and risk as detailed in the main body of the article.

Heather Simmonds

director

Prescription Medicines Code of Practice Authority,

London SW1Y 2DY

Drug misuse should always be considered in young people with impaired consciousness

Entriör—We agree with Ikeda et al that the absence of systolic hypertension may provide some discriminatory power towards exclusion of brain lesions, bechaemic, haemorrhagic, or space occupying in nature. However, we disagree with them that neurological examination of patients with impaired consciousness is often a waste of time and resources and can delay diagnosis.

Although hypertension may be an important potential marker, a careful neurological examination of the papillary response, reflexes, and fundoscopy is an important part of the assessment of any patient with impaired consciousness. Furthermore, we would like to raise concern over the idea that impaired consciousness in conjunction with systolic hypertension implies that a brain lesion is present. This may be true for older people (the mean age in the Ikeda study was 65 years), but in our experience, impaired consciousness with systolic hypertension in younger people (<30 years) implies ingestion of sympathomimetic drugs—for example, ecstasy, amphetamine, cocaine.

Hypertension secondary to ingestion of sympathomimetic drugs requires urgent correction (usually with intravenous nitrates) to prevent secondary complications such as intracerebral haemorrhage, renal failure,
and myocardial ischaemia; if, as is said by Ikeda et al, the hypertension and impaired consciousness are assumed to be related to a brain lesion, the delays in obtaining imaging investigations could lead to delays in instituting potentially life-saving treatment.

The possibility of illicit drug ingestion should be considered in any young, hypertensive patient presenting to an emergency department with reduced consciousness, so that appropriate management can be started without delay.

Kim Whelan registrar in toxicology kwhelan@gsst.sthames.nhs.uk

Alison Jones consultant physician
Paul Morgan registrar in toxicology National Poisons Information Service, Guy’s and St Thomas’ NHS Trust, London SE1 5ER


Unit of analysis errors should be clarified in meta-analyses

Ennror—Weingarten et al present a comprehensive study in what is a complex area of research. We were, however, unclear whether any of the included primary studies had unit of analysis errors and how the authors dealt with such studies in their meta-analysis.

Unit of analysis errors occur in cluster randomised trials when individual patients’ data are analysed as if there was no clustering in the provider, practice, or units randomised to the intervention groups (patients’ data are analysed as independent observations). Standard statistical methods that do not account for cluster effects in cluster randomised trial data result in the overestimation of the significance of an intervention (artificially extreme P values and overly narrow confidence intervals). Correspondingly, the inclusion of studies with unit of analysis errors in a meta-analysis will give greater weight to the results of such studies.

The table of included studies reported by Weingarten et al indicated that the unit of analysis differed from the unit of randomisation in 22 cluster randomised trials, but it was not clear from the report how often unit of analysis errors occurred in these studies or how the authors dealt with studies with such errors in the meta-analysis. Methods exist for re-analysing studies with such errors. We recently completed a systematic review of guideline dissemination and implementation strategies; 51 out of 110 cluster randomised trials had unit of analysis errors, and reanalysis was possible in only one study. Poor reporting of cluster randomised trials has led to a proposed extension to the CONSORT statement, which is currently under discussion. Systematic reviews of studies with unit of analysis errors should clearly state how they handled such studies in a review.

Ruth E Thomas research fellow r.e.thomas@abdn.ac.uk

Craig R Ramsay senior statistician
Health Services Research Unit, University of Aberdeen, Aberdeen AB2 2DD

Laura McAuley review group coordinator
Cochrane Effective Practice and Organisation of Care Group, Cochrane Effective Practice and Organisation of Care Group, Institute of Population Health, University of Ottawa, 1 Stewart Street, Ottawa, ON, Canada K1N 6N5

Jeremy M Grimshaw director, clinical epidemiology programme Institute of Population Health, University of Ottawa, Ottawa Health Research Institute, 1053 Carling Avenue, Ottawa, ON, Canada K1Y 4G9


GPs can separate oncological wheat from chaff

Ennror—Summerton’s editorial on identifying symptoms potentially indicating an underlying cancer in primary care calls for research based theory. Only community based studies will help general practitioners to decide on the importance of a symptom or physical sign reported by their patients as hospital series are unrepresentative.

Although selection bias is part of the problem, it may be comparatively minor as most patients with cancer are treated in secondary care, even though their disease is diagnosed in primary care. Perhaps more important is bias from the development of symptoms in the time from the first symptom appearing to presentation in primary care and finally hospital.

General practitioners are already quite successful in sifting out the wheat from the chaff (although the comparative rarity of cancer in primary care indicates that a better farming analogy would be finding a needle in the haystack). For example, an estimated positive predictive value for colorectal cancer of rectal bleeding in the community is 0.1%.

Once it is reported to the doctor this rises to 2-3%, in patients referred for investigation it is 5.2%.

William T Hamilton lead researcher
12 Bannfield Hill, Exeter EX1 1SR
w.t.hamilton@btopenworld.com

Alison P Round public health consultant
Dean Clarke House, Exeter EX1 1PQ

Deborah Sharp professor
Tim Peters professor
Division of Primary Care, University of Bristol, Bristol BS6 6JH

1 Summerton N. Symptoms of possible oncological significance: separating the wheat from the chaff. BMJ 2002;325:235-6 (50 November).


Look before you flush

Ennror—Moayyedi and Ford described recent advances in gastroenterology. The national programme for early detection of colon cancer uses the following statement to raise public awareness for early detection of rectal bleeding: “Look at it before you flush it.” It is really helpful to make people aware of looking for early signs of colon cancer, but I have noticed some important things that might hinder this national programme.

The lavyatory disinfectants now sold in supermarkets are mostly blue in colour and change water blue, which makes looking for any blood quite difficult. I suggest that we stop selling colouring agents and replace them by colourless ones or even use reagents that turn a certain colour in the presence of minor blood amounts. Can we?

Mourad Ibrahim Habib clinical research fellow
St James’s University Hospitals, Leeds LS9 7TF
mouradhabib@hotmail.com


Correction

Open letter to Tony Blair: Call to prevent escalating violence

An editorial error occurred in this open letter to Tony Blair (p 220, 25 January). By adding “the” to the authorship line we implied that the letter had been signed by all staff, students, and alumni of the London School of Hygiene and Tropical Medicine. The authorship line should have read: “On behalf of 500 public health consultant Mourad Ibrahim Habib clinical research fellow St James’s University Hospitals, Leeds LS9 7TF mouradhabib@hotmail.com”.

bmj.com

Letters appearing here are an edited selection of rapid responses originally posted on bmj.com. We ask for all letters to the editor to be submitted as rapid responses via bmj.com. For advice see: bmj.com/rapidresponses